Founded in Blacksburg, United States, Synthonics is a privately-held specialty pharmaceutical company dedicated to the discovery and development of patentable drugs using proprietary metal coordination chemistry. The company's core mission is to enhance the absorption and therapeutic benefits of pharmaceutical agents by binding them with metals. Synthonics focuses on creating new, more effective drugs that offer greater therapeutic benefits than existing treatments.
Synthonics has established itself as a global leader in Metal Coordination Pharmaceuticals (MCPs), holding active US patents with numerous others pending. The company has made significant strides in the pharmaceutical industry by leveraging the medicinal properties of metals, a concept acknowledged for millennia. Synthonics' innovative approach has garnered attention from notable investors and industry leaders, contributing to its growing impact on modern medicine.
